- Home
- TLPH vs GNTA Comparison
TLPH vs GNTA Comparison
Compare TLPH & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLPH
- GNTA
- Stock Information
- Founded
- TLPH 2005
- GNTA 2014
- Country
- TLPH United States
- GNTA Italy
- Employees
- TLPH N/A
- GNTA N/A
- Industry
- TLPH Biotechnology: Pharmaceutical Preparations
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TLPH Health Care
- GNTA Health Care
- Exchange
- TLPH Nasdaq
- GNTA Nasdaq
- Market Cap
- TLPH 64.7M
- GNTA 59.7M
- IPO Year
- TLPH 2011
- GNTA 2021
- Fundamental
- Price
- TLPH $1.34
- GNTA $2.03
- Analyst Decision
- TLPH Strong Buy
- GNTA
- Analyst Count
- TLPH 1
- GNTA 0
- Target Price
- TLPH $6.00
- GNTA N/A
- AVG Volume (30 Days)
- TLPH 318.3K
- GNTA 2.0M
- Earning Date
- TLPH 11-12-2025
- GNTA 01-01-0001
- Dividend Yield
- TLPH N/A
- GNTA N/A
- EPS Growth
- TLPH N/A
- GNTA N/A
- EPS
- TLPH N/A
- GNTA N/A
- Revenue
- TLPH $28,000.00
- GNTA N/A
- Revenue This Year
- TLPH N/A
- GNTA N/A
- Revenue Next Year
- TLPH $14,533.26
- GNTA N/A
- P/E Ratio
- TLPH N/A
- GNTA N/A
- Revenue Growth
- TLPH N/A
- GNTA N/A
- 52 Week Low
- TLPH $0.38
- GNTA $1.95
- 52 Week High
- TLPH $1.45
- GNTA $10.00
- Technical
- Relative Strength Index (RSI)
- TLPH 57.82
- GNTA 40.65
- Support Level
- TLPH $1.01
- GNTA $2.15
- Resistance Level
- TLPH $1.35
- GNTA $2.32
- Average True Range (ATR)
- TLPH 0.11
- GNTA 0.23
- MACD
- TLPH -0.01
- GNTA -0.04
- Stochastic Oscillator
- TLPH 80.49
- GNTA 9.16
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.